The Semaglutidealso known by its trade names Ozempic and Wegovy, failed to stop the progression of Alzheimer’s disease in two Phase 3 clinical trials involving 3,808 people, the company Novo Nordisk reported today.
In clinical trials Previous studies demonstrating the effectiveness of semaglutide against diabetes had surprisingly found a lower risk of developing Alzheimer’s symptoms in people taking the drug.
This observation prompted Novo Nordisk to conduct two large clinical trials evoke and evoke+to evaluate the effectiveness of the drug against Alzheimer’s disease.
Novo Nordisk is completing clinical trials a year ahead of schedule after finding the treatment was not effective
These studies had raised great expectations because, if its effectiveness were confirmed, it would have been the first affordable, safe and widely available drug to combat the disease. Progression of Alzheimer’s disease.
However, “the evoke and evoke+no trials confirmed the superiority of semaglutide over placebo in reducing the progression of Alzheimer’s disease,” Novo Nordisk reported in a statement.
Nevertheless, the company notes that “treatment with semaglutide resulted in a Improvement of biomarkers Association with Alzheimer’s disease in the two studies.
The participants in evoke and evoke+ were people over 55 years old with a diagnosis of Alzheimer’s and with Symptoms of mild cognitive impairment or mild dementia.
They received the medication orally in tablet form. That was to be expected in this group, Semaglutide could delay the progression of symptoms and prolong the time without disability.
The most important results of clinical studies They were introduced on December 3rd at a conference in San Diego and full results will be released in March 2026, the company reported.
Although the two clinical trials should continue until October 2026, After analyzing the previous results, Novo Nordisk has decided to end it now.
About The Author
